Thank you.
This is to Mr. Nakagawa.
The CDR touts evidence-based decision-making. Why is it that other countries, such as Sweden, Switzerland, and the U.K., are approving much greater access—more than 50% more—to innovative medicines for their citizens? Given that they are reviewing the same drugs, the same science, the same evidence base, why is the CDR blocking access to these same innovative therapies for Canadians?
I'm going to go a little further. Why are patients in Quebec provided with greater access to more innovative medicines in less time than those on a CDR-participating plan? And if I may say so, sir, you're explanation that somehow the science may be viewed differently in Quebec is baffling, at best.
I'll give you a chance to respond to all that.